Wang, C., An, S., & Liu, F. Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”. BMJ Publishing Group.
Chicago Style (17th ed.) CitationWang, Chenglong, Shuai An, and Fang-Tong Liu. Comment on “Phase 2 Study of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, and S-1 with Surgery and Adjuvant Durvalumab Plus S-1 for Resectable Locally Advanced Gastric Cancer”. BMJ Publishing Group.
MLA (9th ed.) CitationWang, Chenglong, et al. Comment on “Phase 2 Study of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, and S-1 with Surgery and Adjuvant Durvalumab Plus S-1 for Resectable Locally Advanced Gastric Cancer”. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.